Overview of literature on fertility and reproductive outcomes after gestational trophoblastic neoplasia treated with multi-agent chemotherapy
| Reference | Chemotherapy | Number of patients with pregnancy wish n | Number of pregnant women n | Number of pregnancies n | Outcome of pregnancies | |||||||
| Miscarriage n (%) | TOP n (%) | Ectopic n (%) | Live birth n (%) | Preterm birth n (%) | Stillbirth n (%) | Cong abn n (%) | Repeat mole n (%) | |||||
| Ross55 | Multi agent | 18 | 7 | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| Woolas et al35 | Multi-agent | 321 | 280 | ND | 35 (12.5) | ND | ND | ND | ND | ND | ND | ND |
| Blagden et al36 | EMA/CO | ND | 77 | ND | 14 (18) | 18 (23) | 0 (0) | 44 (57) | ND | 0 (0) | 1 (1.3) | 2 (2.6) |
| Lok et al9 | EMA/CO | 14 | 12 | 21 | 2 (9.5) | 1 (4.8) | 0 (0) | 16 (76.2) | 2 (9.5) | 0 (0) | 2 (9.5) | 0 (0) |
| Goto et al 39 | Multi-agent | 50 | 23 | 43 | 4 (9.3) | 4 (9.3) | 0 (0) | 34 (79.1) | 0 (0) | 0 (0) | 3 (7.0) | 0 (0) |
| Braga et al41 | EMA/CO, MAC, CHAMOCA, EP/EMA | ND | ND | 54 | 23 (42.6) | ND | ND | 31 (57.4) | 2 (3.7) | 0 (0) | ND | ND |
| Williams et al56 | EMA/CO | ND | 71 | 73 | 4 (5.8) | 8 (11) | 1 (1.4) | 57 (78) | 6 (8.2) | 1 (1.4) | ND | 2 (2.7) |
| Wong et al32 | EMA/CO | 5 | 8 | 19 | 4 (21) | 1 (5) | 0 (0) | 14 (74) | ND | 0 (0) | 2 (11) | ND |
| Cioffi et al31 | Multi-agent | 18 | 12 | 18 | 3 (16.7) | 0 | 0 | 15 (83.3) | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) |
Cong abn, congenital abnormalities; CHAMOCA, cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, doxorubicin, melphalan, vincristine; EMA/CO, etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine; EP/EMA, etoposide, cisplatin, etoposide methotrexate, actinomycin D; MAC, methotrexate, actinomycin D, chlorambucil; ND, not described; TOP, termination of pregnancy.